As Anthropic pushes deeper into life sciences, the FDA is sharpening rules around AI‑enabled research and the use of computational predictions in regulated development pipelines.
Biopharmaceutical
The pilot cohort selected for the PreCheck will test early facility reviews aimed at boosting US pharmaceutical manufacturing capacity and strengthening the domestic drug supply chain.
Several legislative proposals, actions, and regulations are underway in parallel, all at different stages of maturity and all subject to significant political uncertainty.
America’s early-stage clinical trials have increasingly moved overseas, raising concerns about the nation’s long-term competitiveness in biomedical innovation.
The update aims to clarify how manufacturers should approach similarity assessments, indication extrapolation, and post-market safety monitoring.
The partnership will introduce Anthropic’s Claude’s agentic AI capabilities into research, clinical development, manufacturing, commercial operations, and corporate functions.
Makary stepped down amid a widening rift over tobacco regulation and a series of contentious decisions that reshaped the FDA’s internal politics.
The regulator said the goal is to speed up the development of promising therapies by addressing longstanding early-phase delays.